Logo image of LSB

LAKESHORE BIOPHARMA CO LTD (LSB) Stock Fundamental Analysis

NASDAQ:LSB - KYG9845F2080 - Common Stock

0.8001 USD
+0 (+0.01%)
Last: 8/29/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LSB. LSB was compared to 547 industry peers in the Biotechnology industry. LSB may be in some trouble as it scores bad on both profitability and health. LSB is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LSB has reported negative net income.
LSB had a negative operating cash flow in the past year.
In the past 5 years LSB always reported negative net income.
In the past 5 years LSB always reported negative operating cash flow.
LSB Yearly Net Income VS EBIT VS OCF VS FCFLSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

LSB has a better Return On Assets (-7.31%) than 85.92% of its industry peers.
LSB has a better Return On Equity (-20.01%) than 85.19% of its industry peers.
Industry RankSector Rank
ROA -7.31%
ROE -20.01%
ROIC N/A
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSB Yearly ROA, ROE, ROICLSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

LSB has a better Gross Margin (82.47%) than 85.92% of its industry peers.
The Profit Margin and Operating Margin are not available for LSB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSB Yearly Profit, Operating, Gross MarginsLSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

LSB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LSB has more shares outstanding
The debt/assets ratio for LSB is higher compared to a year ago.
LSB Yearly Shares OutstandingLSB Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
LSB Yearly Total Debt VS Total AssetsLSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.96, we must say that LSB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.96, LSB is in line with its industry, outperforming 53.20% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that LSB is not too dependend on debt financing.
LSB has a worse Debt to Equity ratio (0.05) than 60.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -1.96
ROIC/WACCN/A
WACC5.16%
LSB Yearly LT Debt VS Equity VS FCFLSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

LSB has a Current Ratio of 1.02. This is a normal value and indicates that LSB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.02, LSB is not doing good in the industry: 86.65% of the companies in the same industry are doing better.
LSB has a Quick Ratio of 1.02. This is a bad value and indicates that LSB is not financially healthy enough and could expect problems in meeting its short term obligations.
LSB has a worse Quick ratio (0.75) than 89.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.75
LSB Yearly Current Assets VS Current LiabilitesLSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

LSB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.13%, which is quite impressive.
LSB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.24%.
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to decrease by -19.01% on average over the next years. This is quite bad
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
LSB Yearly Revenue VS EstimatesLSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 500M 1B
LSB Yearly EPS VS EstimatesLSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSB. In the last year negative earnings were reported.
LSB is valuated cheaply with a Price/Forward Earnings ratio of 5.59.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LSB indicates a rather cheap valuation: LSB is cheaper than 98.72% of the companies listed in the same industry.
LSB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.72.
Industry RankSector Rank
PE N/A
Fwd PE 5.59
LSB Price Earnings VS Forward Price EarningsLSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSB Per share dataLSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LAKESHORE BIOPHARMA CO LTD

NASDAQ:LSB (8/29/2025, 8:00:00 PM)

0.8001

+0 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)12-15 2025-12-15
Inst Owners3.18%
Inst Owner ChangeN/A
Ins Owners13.8%
Ins Owner ChangeN/A
Market Cap32.97M
Analysts80
Price Target31.62 (3852.01%)
Short Float %0.89%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.59
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)0.14
Fwd EY17.88%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS2.09
BVpS1.7
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.31%
ROE -20.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.48%
FCFM N/A
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.73%
Cap/Sales 2.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.75
Altman-Z -1.96
F-Score4
WACC5.16%
ROIC/WACCN/A
Cap/Depr(3y)103.04%
Cap/Depr(5y)328.9%
Cap/Sales(3y)6.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%
EBIT growth 1Y82.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.02%
OCF growth 3YN/A
OCF growth 5YN/A